Treating the cells with the cytokine cocktail while they are out of the body not only reduces their expression of CD38, a marker of exhaustion, but it also helps to ensure their function and ...

It is thought that CD38-expressing cells contribute to disease ... in the kidneys and cause inflammation and loss of kidney function. Felzartamab's mode of action is to deplete those antibody ...

While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...

Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical ...

Company Announcement <li /> Johnson & Johnson has decided that it will not exercise its option to receive a ...